NCT02820610

Brief Summary

It is important to keep children undergoing laparoscopic surgery pain free with rapid return to normal activity.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
97

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Aug 2016

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 29, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 1, 2016

Completed
1 month until next milestone

Study Start

First participant enrolled

August 1, 2016

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2019

Completed
Last Updated

January 3, 2020

Status Verified

January 1, 2020

Enrollment Period

3.1 years

First QC Date

June 29, 2016

Last Update Submit

January 1, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Postoperative pain

    The Face Legs Activity Cry and Consolability (FLACC) pain score

    48 hr

Secondary Outcomes (1)

  • the functional recovery

    48 hours after surgery

Study Arms (3)

Dexmedetomidine

ACTIVE COMPARATOR

2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity

Drug: Dexmedetomidine

Magnesium sulfate

ACTIVE COMPARATOR

2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity

Drug: Magnesium Sulfate

Control group

PLACEBO COMPARATOR

2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.

Drug: Normal saline 0.9 %

Interventions

2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity

Also known as: Presidx
Dexmedetomidine

2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity

Magnesium sulfate

2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.

Control group

Eligibility Criteria

Age1 Year - 6 Years
Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • age (1 to 6 years)
  • ASA physical status I or II.
  • scheduled for laparoscopic hernia repair under general anesthesia.

You may not qualify if:

  • Allergy to study drugs,
  • Receiving chronic pain treatment, antiepileptic therapy or magnesium therapy,
  • sever hepatic or renal impairment,

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine Assuit University

Asyut, Assuit, 71516, Egypt

Location

MeSH Terms

Conditions

Agnosia

Interventions

DexmedetomidineMagnesium SulfateSaline Solution

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsMagnesium CompoundsInorganic ChemicalsSulfatesSulfuric AcidsSulfur AcidsSulfur CompoundsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer

Study Record Dates

First Submitted

June 29, 2016

First Posted

July 1, 2016

Study Start

August 1, 2016

Primary Completion

September 1, 2019

Study Completion

September 1, 2019

Last Updated

January 3, 2020

Record last verified: 2020-01

Data Sharing

IPD Sharing
Will share

Locations